340 related articles for article (PubMed ID: 32473611)
41. Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis.
Kobayashi H; Yamada Y; Kawahara N; Ogawa K; Yoshimoto C
Oncol Rep; 2019 Mar; 41(3):1729-1738. PubMed ID: 30592289
[TBL] [Abstract][Full Text] [Related]
42. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
43. [Endometriosis-related ovarian tumors].
Schmidt D; Ulrich U
Pathologe; 2014 Jul; 35(4):348-54. PubMed ID: 24992974
[TBL] [Abstract][Full Text] [Related]
44. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
45. Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?
Gounaris I; Charnock-Jones DS; Brenton JD
J Pathol; 2011 Oct; 225(2):157-60. PubMed ID: 21898874
[TBL] [Abstract][Full Text] [Related]
46. Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium.
Yamaguchi M; Nakaoka H; Suda K; Yoshihara K; Ishiguro T; Yachida N; Saito K; Ueda H; Sugino K; Mori Y; Yamawaki K; Tamura R; Revathidevi S; Motoyama T; Tainaka K; Verhaak RGW; Inoue I; Enomoto T
Nat Commun; 2022 Feb; 13(1):943. PubMed ID: 35177608
[TBL] [Abstract][Full Text] [Related]
47. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE; Miller A; Soslow RA; Lankes HA; DeLair D; Segura S; Chavan S; Zamarin D; DeBernardo R; Moore K; Moroney J; Shahin M; Thaker PH; Wahner-Hendrickson AE; Aghajanian C
Gynecol Oncol; 2023 Sep; 176():16-24. PubMed ID: 37418832
[TBL] [Abstract][Full Text] [Related]
48. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.
Guo C; Ren F; Wang D; Li Y; Liu K; Liu S; Chen P
Oncol Rep; 2014 Dec; 32(6):2580-8. PubMed ID: 25333219
[TBL] [Abstract][Full Text] [Related]
49. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
50. The role of p53 mutation in the carcinomas arising from endometriosis.
Akahane T; Sekizawa A; Purwosunu Y; Nagatsuka M; Okai T
Int J Gynecol Pathol; 2007 Jul; 26(3):345-51. PubMed ID: 17581423
[TBL] [Abstract][Full Text] [Related]
51. Pathogenesis of endometrium-related diseases based on genomic alterations in normal uterine endometrium.
Yoshihara K
J Obstet Gynaecol Res; 2023 Aug; 49(8):2023-2030. PubMed ID: 37226598
[TBL] [Abstract][Full Text] [Related]
52. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
53. Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma.
King CM; Barbara C; Prentice A; Brenton JD; Charnock-Jones DS
J Pathol; 2016 Jan; 238(2):185-96. PubMed ID: 26456077
[TBL] [Abstract][Full Text] [Related]
54. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
[TBL] [Abstract][Full Text] [Related]
55. Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.
Yong PJ; Talhouk A; Anglesio MS
Reprod Sci; 2021 Oct; 28(10):2743-2757. PubMed ID: 33469880
[TBL] [Abstract][Full Text] [Related]
56. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer.
Prowse AH; Manek S; Varma R; Liu J; Godwin AK; Maher ER; Tomlinson IP; Kennedy SH
Int J Cancer; 2006 Aug; 119(3):556-62. PubMed ID: 16506222
[TBL] [Abstract][Full Text] [Related]
57. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract][Full Text] [Related]
58. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
59. Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.
Wu RC; Veras E; Lin J; Gerry E; Bahadirli-Talbott A; Baras A; Ayhan A; Shih IM; Wang TL
Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 29162652
[TBL] [Abstract][Full Text] [Related]
60. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
